{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T03:56:38Z","timestamp":1771991798634,"version":"3.50.1"},"reference-count":105,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT02565758"],"award-info":[{"award-number":["NCT02565758"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03234712"],"award-info":[{"award-number":["NCT03234712"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03368859"],"award-info":[{"award-number":["NCT03368859"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","award":["NCT02008383"],"award-info":[{"award-number":["NCT02008383"]}],"id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","award":["NCT02650713"],"award-info":[{"award-number":["NCT02650713"]}],"id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","award":["NCT02715531"],"award-info":[{"award-number":["NCT02715531"]}],"id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","award":["NCT02248805"],"award-info":[{"award-number":["NCT02248805"]}],"id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","award":["NCT02503774"],"award-info":[{"award-number":["NCT02503774"]}],"id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","award":["NCT03435640"],"award-info":[{"award-number":["NCT03435640"]}],"id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["NCT02545504"],"award-info":[{"award-number":["NCT02545504"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["NCT01661972"],"award-info":[{"award-number":["NCT01661972"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.clcc.2018.11.002","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T23:43:08Z","timestamp":1542325388000},"page":"e117-e129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice"],"prefix":"10.1016","volume":"18","author":[{"given":"Tanios","family":"Bekaii-Saab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-1997","authenticated-orcid":false,"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7579-1175","authenticated-orcid":false,"given":"John H.","family":"Strickler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Malka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Sartore-Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald W.","family":"Prager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2018.11.002_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdx738","article-title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS","volume":"29","author":"Yoshino","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib2","first-page":"372","article-title":"Treatment of patients with metastatic colorectal cancer in a real-world scenario: probability of receiving second and further lines of therapy and description of clinical benefit","volume":"16","author":"Tampellini","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2018.11.002_bib3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2017.04.007","article-title":"Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies","volume":"59","author":"Vogel","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clcc.2018.11.002_bib4","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.6004\/jnccn.2017.0036","article-title":"Colon cancer, version 1.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Benson","year":"2017","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clcc.2018.11.002_bib6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.6004\/jnccn.2015.0087","article-title":"Rectal cancer, version 2.2015","volume":"13","author":"Benson","year":"2015","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clcc.2018.11.002_bib8","author":"Taiho Oncology"},{"key":"10.1016\/j.clcc.2018.11.002_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2018.11.002_bib10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1200\/jco.2013.31.4_suppl.467","article-title":"Time course of regorafenib-associated adverse events in the phase III CORRECT study","volume":"31","author":"Grothey","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"issue":"Suppl 9","key":"10.1016\/j.clcc.2018.11.002_bib12","first-page":"42","article-title":"140O - Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC)","volume":"26","author":"Van Cutsem","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib13","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1200\/JCO.2017.35.15_suppl.3567","article-title":"Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): an interim analysis from the prospective, observational CORRELATE study","volume":"35","author":"Ducreux","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12885-016-2440-9","article-title":"Survival, safety, and prognostic factors for outcome with regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program","volume":"16","author":"Adenis","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2018.11.002_bib15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.2017.35.4_suppl.769","article-title":"Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: interim results of the prospective multicentre noninterventional RECORA study","volume":"35","author":"Schulz","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11523-016-0458-1","article-title":"Regorafenib in the real-life clinical practice: data from the Czech Registry","volume":"12","author":"Kopeckova","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4137\/CMO.S38335","article-title":"Efficacy, safety and cost of regorafenib in patients with metastatic colorectal cancer in French clinical practice","volume":"10","author":"Calcagno","year":"2016","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib18","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study","volume":"36","author":"Xu","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2017.35.4_suppl.721","article-title":"Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC)","volume":"35","author":"Komatsu","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1634\/theoncologist.2017-0275","article-title":"Propensity score analysis of regorafenib versus trifluridine\/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum multicenter observational study","volume":"23","author":"Moriwaki","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2018.11.002_bib21","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2018.11.002_bib22","doi-asserted-by":"crossref","first-page":"512P","DOI":"10.1093\/annonc\/mdw370.60","article-title":"Compassionate use program for trifluridine\/tipiracil (TAS-102) in metastatic colorectal cancer: a real-life overview","volume":"27","author":"Salvatore","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib23","first-page":"e205","article-title":"TAS-102 safety in metastatic colorectal cancer: results from the first postmarketing surveillance study","volume":"15","author":"Yoshino","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2018.11.002_bib24","author":"Bayer"},{"key":"10.1016\/j.clcc.2018.11.002_bib25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/17512433.2016.1133285","article-title":"A\u00a0novel antimetabolite: TAS-102 for metastatic colorectal cancer","volume":"9","author":"Miyamoto","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.clcc.2018.11.002_bib28","author":"Food and Drug Administration"},{"key":"10.1016\/j.clcc.2018.11.002_bib29","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib30","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1200\/JCO.2018.36.4_suppl.554","article-title":"Nivolumab in patients with DNA mismatch repair-deficient\/microsatellite instability-high (dMMR\/MSI-H) metastatic colorectal cancer (mCRC): long-term survival according\u00a0to prior line of treatment from CheckMate-142","volume":"36","author":"Overman","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib31","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1200\/JCO.2017.35.15_suppl.3071","article-title":"Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC","volume":"35","author":"Diaz","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib32","author":"Merck & Co"},{"key":"10.1016\/j.clcc.2018.11.002_bib33","author":"Bristol-Myers Squibb"},{"key":"10.1016\/j.clcc.2018.11.002_bib34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/jamaoncol.2017.3323","article-title":"Human epidermal growth factor receptor 2 as a molecular biomarker for metastatic colorectal cancer","volume":"4","author":"Sartore-Bianchi","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib35","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib36","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib37","doi-asserted-by":"crossref","first-page":"506P","DOI":"10.1093\/annonc\/mdw370.54","article-title":"Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS)\u00a0>4 months (m)","volume":"27","author":"Garcia-Carbonero","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib38","doi-asserted-by":"crossref","first-page":"515P","DOI":"10.1093\/annonc\/mdw370.63","article-title":"RECOURSE trial: Performance status at discontinuation in patients receiving trifluridine\/tipiracil (TAS-102)","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib39","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","article-title":"TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial","volume":"13","author":"Yoshino","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib40","doi-asserted-by":"crossref","first-page":"e15043","DOI":"10.1200\/JCO.2017.35.15_suppl.e15043","article-title":"TAS 102 in refractory metastatic colorectal cancer: UK Expanded Access Programme experience","volume":"35","author":"O\u2019Brien","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib41","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1200\/jco.2016.34.4_suppl.638","article-title":"TAS-102 versus placebo (PBO) in patients (pts)\u00a0\u226565 years (y) with metastatic colorectal cancer (mCRC): an age-based analysis of the recourse trial","volume":"34","author":"Van Cutsem","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib42","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1200\/JCO.2016.34.15_suppl.3524","article-title":"Regorafenib in previously treated metastatic colorectal cancer (mCRC): analysis of age subgroups in the open-label phase IIIb CONSIGN trial","volume":"34","author":"Van Cutsem","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib43","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib44","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2018.36.4_suppl.557","article-title":"REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan","volume":"36","author":"Shitara","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib45","first-page":"141","article-title":"Molecular subtypes and personalized therapy in metastatic colorectal cancer","volume":"12","author":"Graham","year":"2016","journal-title":"Curr Colorectal Cancer Rep"},{"key":"10.1016\/j.clcc.2018.11.002_bib46","doi-asserted-by":"crossref","first-page":"S332","DOI":"10.1016\/S0959-8049(16)30937-6","article-title":"2013 analysis of biomarkers in circulating tumor DNA from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC): correlation with clinical outcome","volume":"51","author":"Teufel","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2018.11.002_bib47","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S1470-2045(15)00138-2","article-title":"Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.clcc.2018.11.002_bib48","article-title":"534P: exploratory analysis of baseline microsatellite instability (MSI) status in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) or placebo in the phase 3 CORRECT trial","volume":"28","author":"K\u00f6chert","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib49","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.clcc.2018.11.002_bib50","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000479280","article-title":"Serum CA19-9 response is an early predictive marker of efficacy of regorafenib in refractory metastatic colorectal cancer","volume":"93","author":"Komori","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.clcc.2018.11.002_bib51","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/JCO.2017.35.4_suppl.596","article-title":"Role of genetic polymorphisms in CCL5\/CCR5 axis to predict efficacy of regorafenib in patients with refractory metastatic colorectal cancer","volume":"35","author":"Suenaga","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib52","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/annonc\/mdx035","article-title":"Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer","volume":"28","author":"Suenaga","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib53","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1200\/JCO.2017.35.4_suppl.615","article-title":"Genetic variants of genes in CCL5\/CCR5 pathway to predict regorafenib-induced hand-foot skin reaction in patients with refractory metastatic colorectal cancer: a report of ethnic difference","volume":"35","author":"Suenaga","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib54","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.clcc.2018.11.002_bib55","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/annonc\/mdy140","article-title":"Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer","volume":"29","author":"Cremolini","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib56","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.2017.35.4_suppl.741","article-title":"Prognostic impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) at the salvage lines","volume":"35","author":"Nagaoka","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib57","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/jco.2014.32.15_suppl.3511","article-title":"Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes","volume":"32","author":"Dienstmann","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.clcc.2018.11.002_bib58","article-title":"LBA-004 Efficacy and safety results from IMblaze370, a randomised phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer","volume":"29","author":"Bendell","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib59","doi-asserted-by":"crossref","first-page":"20713","DOI":"10.1200\/jco.2008.26.15_suppl.20713","article-title":"Patient interviews on hand-foot syndrome: symptom assessment and impact on quality of life","volume":"26","author":"Aklilu","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib60","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s10637-014-0154-x","article-title":"Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations","volume":"33","author":"Yoshino","year":"2015","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clcc.2018.11.002_bib61","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","article-title":"Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management","volume":"26","author":"McLellan","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib62","first-page":"e39","article-title":"Prophylactic use of oral dexamethasone to alleviate fatigue during regorafenib treatment for patients with metastatic colorectal cancer","volume":"16","author":"Fukuoka","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2018.11.002_bib63","first-page":"837","article-title":"Prevention and management of adverse events related to regorafenib","volume":"22","author":"De Wit","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clcc.2018.11.002_bib64","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000382067","article-title":"Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events","volume":"38","author":"Hofheinz","year":"2015","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.clcc.2018.11.002_bib65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1530\/EJE-17-0231","article-title":"Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?","volume":"177","author":"Pani","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clcc.2018.11.002_bib66","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2018.11.002_bib67","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","article-title":"Recommended guidelines for the treatment of cancer treatment-induced diarrhea","volume":"22","author":"Benson","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib68","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1188\/09.CJON.336-341","article-title":"Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy- and radiotherapy-induced diarrhea","volume":"13","author":"Muehlbauer","year":"2009","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clcc.2018.11.002_bib69","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.2018.36.4_suppl.611","article-title":"Regorafenib dose optimization study (ReDOS): randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study","volume":"36","author":"Bekaii-Saab","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib70","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000448717","article-title":"Self-reported adherence to trifluridine and tipiracil hydrochloride for metastatic colorectal cancer: a retrospective cohort study","volume":"91","author":"Sugita","year":"2016","journal-title":"Oncology"},{"issue":"15 Suppl","key":"10.1016\/j.clcc.2018.11.002_bib71","doi-asserted-by":"crossref","first-page":"e15021","DOI":"10.1200\/JCO.2016.34.15_suppl.e15021","article-title":"Supportive treatment for hematologic toxicities in the phase 3 RECOURSE trial of TAS-102 vs placebo with best supportive care in patients with metastatic colorectal cancer","volume":"34","author":"Mayer","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib72","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib73","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib74","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.clcc.2018.11.002_bib75","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s12094-014-1212-8","article-title":"Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer","volume":"16","author":"Sastre","year":"2014","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib76","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/CMAR.S52217","article-title":"Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management","volume":"6","author":"Khan","year":"2014","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clcc.2018.11.002_bib77","first-page":"371","article-title":"Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan","volume":"35","author":"Hirano","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clcc.2018.11.002_bib78","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3892\/mco.2017.1145","article-title":"Response to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancer","volume":"6","author":"Osawa","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib79","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1200\/JCO.2018.36.4_suppl.821","article-title":"Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemotherapy","volume":"36","author":"Kudo","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib80","doi-asserted-by":"crossref","first-page":"e000111","DOI":"10.1136\/esmoopen-2016-000111","article-title":"Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)","volume":"1","author":"Ricotta","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.clcc.2018.11.002_bib81","first-page":"377","article-title":"Predictive value of early tumor shrinkage and density reduction of lung metastases in patients with metastatic colorectal cancer treated with regorafenib","volume":"16","author":"Vanwynsberghe","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2018.11.002_bib82","doi-asserted-by":"crossref","first-page":"45703","DOI":"10.1038\/srep45703","article-title":"Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: the TRIBUTE analysis","volume":"7","author":"Giampieri","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clcc.2018.11.002_bib83","doi-asserted-by":"crossref","first-page":"516P","DOI":"10.1093\/annonc\/mdw370.64","article-title":"Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial","volume":"27","author":"Grothey","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib84","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1200\/JCO.2017.35.15_suppl.3551","article-title":"Hand-foot skin reaction (HFSR) and outcomes in the phase 3 CORRECT trial of regorafenib for metastatic colorectal cancer (mCRC)","volume":"35","author":"Grothey","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib85","first-page":"51","article-title":"Neutropenia as a predictive factor in metastatic colorectal cancer treated with TAS-102","volume":"16","author":"Hamauchi","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2018.11.002_bib86","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12885-016-2491-y","article-title":"Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study","volume":"16","author":"Kasi","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2018.11.002_bib87","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.2017.35.4_suppl.775","article-title":"Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine\/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer","volume":"35","author":"Ohtsu","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 15","key":"10.1016\/j.clcc.2018.11.002_bib88","article-title":"High levels of cell-free DNA (cfDNA) at baseline (BL) and increase of at least one mutation at day 14 (D14) as independent prognostic biomarkers for patients (pts) with advanced colorectal cancer (aCRC) under regorafenib","volume":"36","author":"Kehagias","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib89","first-page":"1959","article-title":"Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer","volume":"36","author":"Arita","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clcc.2018.11.002_bib90","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1016\/j.ejca.2013.07.150","article-title":"Platinum-sensitivity in metastatic colorectal cancer: towards a definition","volume":"49","author":"Chibaudel","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2018.11.002_bib91","first-page":"213","article-title":"Oxaliplatin immune-induced syndrome occurs with cumulative administration and rechallenge: single institution series and systematic review study","volume":"15","author":"Bencardino","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2018.11.002_bib92","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2016.10.006","article-title":"Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR","volume":"51","author":"Sartore-Bianchi","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clcc.2018.11.002_bib93","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/annonc\/mdh305","article-title":"Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer","volume":"15","author":"Maindrault-Goebel","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib94","first-page":"292","article-title":"TAS-102 (Lonsurf) for the treatment of metastatic colorectal cancer. A concise review","volume":"15","author":"Zaniboni","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2018.11.002_bib95","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nm.3870","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat Med"},{"issue":"15 Suppl","key":"10.1016\/j.clcc.2018.11.002_bib96","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/JCO.2018.36.15_suppl.3511","article-title":"Anti-EGFR resistant clones decay exponentially after progression: implications for anti-EGFR rechallenge","volume":"36","author":"Parseghian","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib97","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/annonc\/mdr623","article-title":"Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?","volume":"23","author":"Santini","year":"2012","journal-title":"Ann Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.clcc.2018.11.002_bib98","article-title":"PD-026 rechallenge with cetuximab\u00a0+ irinotecan in 3rd-line in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients with acquired resistance to 1st-line cetuximab\u00a0+ irinotecan: the phase II CRICKET study by GONO","volume":"28","author":"Rossini","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib99","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.2011-0452","article-title":"Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab","volume":"17","author":"Wadlow","year":"2012","journal-title":"Oncologist"},{"issue":"Suppl 3","key":"10.1016\/j.clcc.2018.11.002_bib100","article-title":"P-320 rechallenge with EGFR inhibitors in patients with metastatic colorectal cancer: effect on outcomes","volume":"28","author":"Salvatore","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib101","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","article-title":"TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study","volume":"18","author":"Kuboki","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib102","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/EDBK_200821","article-title":"Where we stand with immunotherapy in colorectal cancer: deficient mismatch repair, proficient mismatch repair, and toxicity management","author":"Overman","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clcc.2018.11.002_bib103","doi-asserted-by":"crossref","first-page":"CT005","DOI":"10.1158\/1538-7445.AM2017-CT005","article-title":"Abstract CT005: final results of the HERACLES trial in HER2-amplified colorectal cancer","volume":"77","author":"Siena","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.clcc.2018.11.002_bib104","doi-asserted-by":"crossref","first-page":"TPS3624","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS3624","article-title":"A\u00a0phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER)","volume":"35","author":"Strickler","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib105","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.clcc.2018.11.002_bib106","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/annonc\/mdt547","article-title":"Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation","volume":"25","author":"Pietrantonio","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib107","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/annonc\/mdw071","article-title":"Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer","volume":"27","author":"Amatu","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.11.002_bib108","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejca.2016.10.032","article-title":"Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients","volume":"71","author":"Sartore-Bianchi","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002818304717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002818304717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:06:05Z","timestamp":1761519965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002818304717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":105,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1533002818304717"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2018.11.002","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2018.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}